← Oncology Approval Tracker

FDA DECISION ·

Keytruda

pembrolizumab · Merck

FDA approvalIndication revisionGastric and gastroesophageal junction cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

First-line pembrolizumab plus fluoropyrimidine and platinum chemotherapy for adults with locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma is limited to tumors with PD-L1 CPS of at least 1.

LAMPGEN ANALYSIS

Why it matters

The update makes PD-L1 expression part of eligibility for this existing HER2-negative combination regimen.

What research teams should watch

Capture both HER2 and PD-L1 results before applying the revised first-line eligibility criteria.

PRIMARY RECORDS

Sources